Zhejiang Wecome Pharmaceutical Company Limited (SHE:300878)

SHE:300878 Revenue

Zhejiang Wecome Pharmaceutical Company had revenue of 52.19M CNY in the quarter ending September 30, 2026, with 42.01% growth. This brings the company's total for the last twelve months to 252.30M, up 91.62% year-over-year. In the year 2025, Zhejiang Wecome Pharmaceutical Company had annual revenue of 225.27M, down -35.86%. That makes Zhejiang Wecome Pharmaceutical Company the 29,877th largest company in the world by revenue and 4,941st in China.

• Revenue (ttm): 252.30M
• Revenue Growth: +91.62%
• P/S Ratio: 16.10
• Revenue / Employee: 471.59K
• Employees: 535
• Market Cap: 4.25B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Pharmaceutical Manufacturing 184.33M 81.8%
• Pharmaceutical Wholesale and Retail 36.35M 16.1%
• Other Operating Revenue/Costs 4.60M 2.0%

Fiscal year ended Dec 31, 2025 See the full SHE:300878 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	225.27M	-125.93M	-35.86%
Dec 31, 2024	351.20M	-168.42M	-32.41%
Dec 31, 2023	519.62M	-12.82M	-2.41%
Jan 1, 2023	532.44M	-100.51M	-15.88%
Jan 1, 2022	632.95M	10.19M	1.64%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error